汉字News

← 汉字NewsChinese News for Learners
technology
kē jì
科技
·HSK 3

Roche (pharmaceutical company)
Luóshì
罗氏
to announce
xuānbù
宣布
to acquire
shōugòu
收购
artificial intelligence
rén gōng zhìnéng
人工智能
pathology
bìnglǐ
病理
company
gōngsī
公司
PathAI (AI pathology company)
PathAI
PathAI
，
deal / transaction
jiāoyì
交易
transaction amount
jīn é
金额
up to / at most
zuìgāo
最高
to reach
dá
达
$1.05 billion
10.5 yì měiyuán
10.5亿美元
。

Switzerland
Ruìshì
瑞士
pharmaceutical
zhìyào
制药
giant / major player
jùtóu
巨头
Roche
Luóshì
罗氏
to announce
xuānbù
宣布
to acquire
shōugòu
收购
United States
Měiguó
美国
artificial intelligence
rén gōng zhìnéng
人工智能
pathology
bìnglǐ
病理
company
gōngsī
公司
PathAI (AI pathology startup)
PathAI
PathAI
，
upfront payment
yùfù
预付
$750 million
7.5 yì měiyuán
7.5亿美元
，
total amount
zǒng jīn é
总金额
up to / at most
zuìgāo
最高
can reach
kě dá
可达
$1.05 billion
10.5 yì měiyuán
10.5亿美元
。

May 19, 2026 at 9:00 AM

Roche
Luóshì
罗氏
on (a date)
yú
于
May 7th
5 yuè 7 rì
5月7日
to announce
xuānbù
宣布
with
yǔ
与
Boston
Bōshìdùn
波士顿
startup company
chūchuàng gōngsī
初创公司
PathAI (AI pathology startup)
PathAI
PathAI
to sign
qiānshǔ
签署
definitive / final
zuìzhōng
最终
merger
hébìng
合并
agreement
xiéyì
协议
。
PathAI
PathAI
PathAI
to focus on
zhuānzhù yú
专注于
for
wèi
为
pathology
bìnglǐ
病理
laboratory
shíyànshì
实验室
and
hé
和
bio- / biological
shēngwù
生物
pharmaceutical
zhìyào
制药
industry
hángyè
行业
to develop
kāifā
开发
artificial intelligence
rén gōng zhìnéng
人工智能
driven by / powered by
qūdòng de
驱动的
diagnostic
zhěnduàn
诊断
tools
gōngjù
工具
。
Roche
Luóshì
罗氏
will / (future marker)
jiāng
将
(object marker)
bǎ
把
PathAI
PathAI
PathAI
to incorporate into
nàrù
纳入
under (a company or brand)
qíxià
旗下
diagnostics
zhěnduàn
诊断
division / department
bùmén
部门
，
in order to
yǐ
以
to strengthen / to enhance
jiāqiáng
加强
its
qí
其
in
zài
在
digital
shùzì
数字
pathology
bìnglǐ
病理
field / domain
lǐngyù
领域
(possessive particle)
de
的
positioning / layout
bùjú
布局
。
the two (companies)
liǎng jiā
两家
companies
gōngsī
公司
since
zì
自
2021
2021 nián
2021年
from / starting from
qǐ
起
already / then
jiù
就
to carry out / to conduct
kāizhǎn
开展
cooperation / partnership
hézuò
合作
，
and in / and at
bìng yú
并于
2024
2024 nián
2024年
to expand
kuòdà
扩大
(completion particle)
le
了
joint / collaborative
liánhé
联合
research and development
yánfā
研发
scope / range
fànwéi
范围
。
this time / on this occasion
cǐ cì
此次
acquisition
shōugòu
收购
expected to / estimated
yùjì
预计
will in / is expected in
jiāng yú
将于
this year
jīn nián
今年
second half of the year
xià bànnián
下半年
to complete / to close
wánchéng
完成
。
if
rúguǒ
如果
relevant / related
xiāngguān
相关
milestone
lǐchéngbēi
里程碑
target / goal
mùbiāo
目标
to be achieved
dáchéng
达成
，
PathAI
PathAI
PathAI
will also
hái jiāng
还将
additional / extra
éwài
额外
to receive / to obtain
huòdé
获得
$300 million
3 yì měiyuán
3亿美元
。
this is
zhè shì
这是
recently / in recent times
jìnqī
近期
pharmaceutical
zhìyào
制药
industry
hángyè
行业
positioning in
bùjú
布局
artificial intelligence
rén gōng zhìnéng
人工智能
diagnostics
zhěnduàn
诊断
(possessive particle)
de
的
yet another
yòu yī
又一
significant / major
zhòngdà
重大
deal / transaction
jiāoyì
交易
。

New Words

Luóshì
罗氏
Roche
shōugòu
收购
to acquire
bìnglǐ
病理
pathology
zhěnduàn
诊断
diagnostic
gōngjù
工具
tools
rén gōng zhìnéng
人工智能
artificial intelligence
bùjú
布局
positioning
hézuò
合作
cooperation
yánfā
研发
research and development
jiāoyì
交易
deal

News in English

Science & Technology

Roche Announces Acquisition of AI Pathology Firm PathAI for Up to $1.05 Billion

Swiss pharmaceutical giant Roche announced the acquisition of US AI pathology company PathAI, with an upfront payment of $750 million and a total deal value of up to $1.05 billion.

Roche announced on May 7th a definitive merger agreement with Boston-based startup PathAI.

PathAI specializes in developing AI-driven diagnostic tools for pathology laboratories and the biopharmaceutical industry.

Roche will incorporate PathAI into its diagnostics division to strengthen its positioning in the field of digital pathology.

The two companies have been collaborating since 2021 and expanded their joint research and development efforts in 2024.

This acquisition is expected to close in the second half of this year.

If relevant milestone targets are achieved, PathAI will receive an additional $300 million.

This is yet another major transaction in the pharmaceutical industry's AI diagnostics positioning.

More in Science & Technology

China
Zhongguó
中国
AI
réngong zhìnéng
人工智能
models
móxíng
模型
captures
zhànlǐng
占领
market
shìchǎng
市场

Chinese AI Models Gain Market Share as GLM 5.2 Rivals OpenAI and Anthropic at Low Cost

UBTech
Yōubìxuǎn
优必选
U1
U1
U1
humanoid robot
rénxíng jīqìrén
人形机器人
launches
fābuō
发布
price
jiàgé
价格

UBTech Launches U1 Ultra-Bionic Humanoid Robot Series Starting at 17600 Dollars

Apple (company)
Píngguǒ
苹果
to file a lawsuit / to sue
qǐsù
起诉
OpenAI (AI company)
OpenAI
OpenAI
，
to accuse / to charge
zhǐkòng
指控
it / the company (formal)
qí
其
to steal / to misappropriate
qièqǔ
窃取
hardware
yìngjiàn
硬件
trade secrets / confidential business information
shāngyè jīmì
商业机密
。

Apple Sues OpenAI Alleging Hardware Trade Secret Theft

Tencent (tech company)
Téngxùn
腾讯
in
zài
在
WeChat (messaging app)
Wēixìn
微信
to launch / roll out
tuīchū
推出
artificial intelligence
réngōng zhìnéng
人工智能
assistant
zhùshǒu
助手
Xiaowei (AI assistant name)
Xiǎowēi
小微
。

Tencent Begins Rolling Out AI Agent Xiaowei to WeChat Users